Bdparib 300mg Tablet

Prostate cancer, Fallopian tube cancer, Ovarian cancer, primary peritoneal cancer.

Undesired symptoms or responses vary from person to person as the human body reacts differently to the Bdparib 300 mg tablet. Still, they typically resolve naturally within a few days as the body adjusts to the medicine, requiring no medical attention. In case these symptoms don't go away and you face severe side effects, then immediately consult your doctor or medical team. Some of the common side effects of the Bdparib 300 mg tablet are:
Headache,
Fever
Loss of appetite
Pain in the eyes
Blurred vision
High blood pressure
Dry skin
lack of sleep.
Vomiting
Indigestion
Nausea Reduced Kidney function, diarrhea, or constipation

Bdparib 300mg tablet is not a drug used for self-medication; it should always be taken as directed by a physician. As advised by the physician, it can be taken either with or without food. Your doctor will decide the dose and timing of the Bdparib 300 mg based on the disease condition and other factors.
For best results in its effectiveness, the Bdparib 300mg tablet must be swallowed rather than chewed, opened, or crushed. It is an oral drug that is given once daily, before meals, at the same time every day. The Bdparib 300mg tablet should not be taken for at least three hours before or after food. Take it as prescribed by the physician.

Bdparib 300mg tablet inhibits the enzyme that plays an important role in DNA repair, by inhibiting poly Adenosine diphosphate-ribose polymerase enzymes such as PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. By blocking an enzyme associated with DNA repair, the spread of cancer cells can be stopped, resulting in their death. Bdparib 300mg tablet does not allow damaged DNA to get repaired.

Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., & Bray, F. (2023). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer, 49(6), 1374-1403.
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., & Oza, A. (2021). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet Oncology, 12(9), 852-861.
Guo, X. X., Wu, H. L., Shi, H. Y., Su, L., & Zhang, X. (2025). The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials. Cancer Management and Research, 2553-2562.
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., & Vergote, I. (2025). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 18(9), 1274-1284.
Zhou, D., Li, J., Learoyd, M., Bui, K., Berges, A., Milenkova, T., & Xu, H. (2024). Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clinical Pharmacology & Therapeutics, 105(6), 1492-1500.